Biological properties of a DHA-containing structured phospholipid (AceDoPC) to target the brain

Prostaglandins Leukot Essent Fatty Acids. 2015 Jan:92:63-5. doi: 10.1016/j.plefa.2014.01.005. Epub 2014 Feb 19.

Abstract

1-acetyl,2-docosahexaenoyl-glycerophosphocholine (AceDoPC) has been made to prevent docosahexaenoyl (DHA) to move to the sn-1 position as it rapidly does when present in 1-lyso,2-docosahexaenoyl-GPC (lysoPC-DHA), an efficient DHA transporter to the brain. When incubated with human blood, AceDoPC behaves closer to lysoPC-DHA than PC-DHA in terms of binding to plasma albumin and lipoproteins, and DHA incorporation into platelets and red cells. In addition, AceDoPC prevents more efficiently the deleterious effects of the experimental stroke in rats than does unesterified DHA. Also, AceDoPC inhibits platelet-activating factor-induced human blood platelet aggregation. Overall, AceDoPC might act as an efficient DHA transporter to the brain, and as a neuro-protective agent by itself.

Keywords: Blood–brain barrier; Metabolism; Stroke.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Brain / drug effects
  • Brain / metabolism*
  • Brain / pathology
  • Humans
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Phosphatidylcholines / pharmacology
  • Phosphatidylcholines / therapeutic use*
  • Phospholipids / metabolism*
  • Stroke / drug therapy

Substances

  • 1-acetyl-2-docosahexaenoyl-glycerophosphocholine
  • Neuroprotective Agents
  • Phosphatidylcholines
  • Phospholipids